Abstract
Objective To evaluate the efficacy and adverse reaction of apatinib in the treatment of advanced gastric cancer. Methods Forty patients with advanced gastric cancer were selected and treated with alteplain of 850 mg once a day for one course of treatment. The efficacy on patients was evaluated, Kaplan-Meier method was used to analyze the disease-free survival (DFS), the influencing factors of DFS in patients and the adverse reactions were observed and evaluated. Results All of the 40 patients were diagnosed with adenocarcinoma. The overall response rate was 5.0% (2/40) and the disease control rate was 42.5% (17/40). The control rate of alpha-fetoprotein-positive (AFP-positive) patients was significantly higher than that of AFP-negative patients (62.5% vs. 37.5%, P=0.025). The median value of DFS was 3.7 months. Kaplan-Meier analysis showed that ECOG and AFP were the influencing factors of DFS (P=0.039 and 0.041, respectively). The most common adverse reactions were leukopenia, hypertension and thrombocytopenia. Conclusions The treatment of advanced gastric cancer can get high efficacy and good tolerance and can improve the disease control rate of patients with advanced gastric cancer and prolong the survival time of patients. It is worth popularizing and applying. Key words: Etpenipine; Advanced gastric cancer; Efficacy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
